Skip to main content
Novavax, Inc. (NVAX)
NASDAQ: NVAX · Real-Time Price · USD
9.98
-0.01 (-0.10%)
Mar 6, 2026, 4:00 PM EST - Market closed

Novavax Revenue by Segment
Period Ending Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021
Product
729.79M 190.44M 391.89M 355.91M 621.17M 531.39M 567.72M 1.19B
Product Growth
17.49% -64.16% -30.97% -70.13% -35.42% -65.83% -55.20% 85.87%
Licensing Royalties and Other
525.86M 492.41M 455.36M 428.89M 35.50M 24.99M 23.09M 5.47M
Licensing Royalties and Other Growth
1,381.50% 1,870.20% 1,872.54% 7,747.96% 36.64% -43.18% -86.51% -97.43%
Grants
- - - - - 427.32M 458.95M 400.30M
Grants Growth
- - - - - 11.60% 12.39% -8.41%

Revenue by Geography
Period Ending Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022
North America
110.79M 65.02M 56.94M 25.21M 23.60M 29.96M 2.23M -
North America Growth
369.51% 117.04% 2,452.35% - - - - -
Rest of World
76.94M 31.92M 33.62M 30.55M 296.06M 233.07M - 593.28M
Rest of World Growth
-74.01% -86.30% - -94.85% -18.91% -56.59% - -
Europe
10.94M 93.27M 301.33M 300.16M 301.51M 268.36M - 468.58M
Europe Growth
-96.37% -65.24% - -35.94% -35.45% -67.41% - -
Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.